Compare Ralph Lauren Corp (RL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs Zoetis Inc — how do they compare? Ralph Lauren Corp trades at $370.78 (market cap $21.89B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ralph Lauren Corp for 84 Days and Zoetis Inc for 70 Days on average.
| RL | ZTS | |
|---|---|---|
Market Cap | $21.89B | $30.20B |
Volume | 481,617 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $147.53 |
52-Week Low | $309.29 | $69.09 |
Typical Hold Time | 84 Days | 70 Days |
Enterprise Value | $22.95B | $37.76B |
Dividend Yield | 1.09% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $370.82, up 2.68% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $7.08B in 2025, net income margin of 11.76%, and consistent earnings beats. Recent news highlights dividend declarations, global expansion, and sustainability progress, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $456.67 implying 23% upside, though risks include competitive pressures and potential economic slowdown. Earnings momentum and brand strength provide tailwinds, but investors should monitor execution on growth initiatives amid market volatility.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
